Related Experiment Video

Updated: Jun 20, 2026

Identification of Transcription Factor Regulators using Medium-Throughput Screening of Arrayed Libraries and a Dual-Luciferase-Based Reporter
11:32

Identification of Transcription Factor Regulators using Medium-Throughput Screening of Arrayed Libraries and a Dual-Luciferase-Based Reporter

Published on: March 27, 2020

In vivo RNAi screening identifies regulators of actin dynamics as key determinants of lymphoma progression

Corbin E Meacham1, Emily E Ho, Esther Dubrovsky

  • 1The Koch Institute for Integrative Cancer Research at MIT, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.

Nature Genetics
|September 29, 2009
PubMed

Insights

Researchers adapted loss-of-function screening in mouse cancer models. This identified key regulators of cell motility as potential lymphoma drug targets, offering new therapeutic strategies for hematopoietic malignancies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Mouse models are crucial for cancer research but limited for genetic screening.
  • Unbiased genetic screens are needed to understand cancer development.
  • Developing new screening methods in vivo is essential.

Purpose of the Study:

  • To adapt loss-of-function screening for mouse cancer models.
  • To identify novel genetic targets in lymphoma.
  • To explore therapeutic strategies for hematopoietic malignancies.

Main Methods:

  • Utilized transplantable Emu-myc lymphoma cells in mice.
  • Introduced a library of short hairpin RNAs (shRNAs) for genetic screening.
  • Performed large-scale genetic screens (nearly 1,000 alterations) in vivo.

Main Results:

  • Identified regulators of actin dynamics and cell motility critical for lymphoma homeostasis.
  • Validated these proteins as potential drug targets for lymphoma.
  • Demonstrated that targeting Rac2 and twinfilin enhances vincristine efficacy.

Conclusions:

  • Loss-of-function screening is feasible and effective in mouse cancer models.
  • Actin dynamics and cell motility regulators are key targets for lymphoma therapy.
  • Targeting cell motility may overcome resistance and prevent relapse in hematopoietic malignancies.

Related Concept Videos

lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA (lncRNA)...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...